Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
News Dec 09, 2010
Stellar Biotechnologies, Inc. has announced that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the technology developed through a Collaborative Research Agreement between Stellar and Bayer Innovations (BIG).
The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development. Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields.
Stellar CEO, Frank Oakes said, ”The technology developed through the collaboration with BIG represents a breakthrough in the production of highly characterized, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product. The technology will be integrated into BIG’s NHL vaccine platform, and commercialized broadly by Stellar for other vaccines and related products.”